Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia
Open Access
- 15 October 2012
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 24 (2), 475-482
- https://doi.org/10.1093/annonc/mds338
Abstract
Intravenous (i.v.) iron can improve anaemia of chronic disease and response to erythropoiesis-stimulating agents (ESAs), but data on its use in practice and without ESAs are limited. This study evaluated effectiveness and tolerability of ferric carboxymaltose (FCM) in routine treatment of anaemic cancer patients. Of 639 patients enrolled in 68 haematology/oncology practices in Germany, 619 received FCM at the oncologist's discretion, 420 had eligible baseline haemoglobin (Hb) measurements, and 364 at least one follow-up Hb measurement. Data of transfused patients were censored from analysis before transfusion. The median total iron dose was 1000 mg per patient (interquartile range 600–1500 mg). The median Hb increase was comparable in patients receiving FCM alone (1.4 g/dl [0.2–2.3 g/dl; N = 233]) or FCM + ESA (1.6 g/dl [0.7–2.4 g/dl; N = 46]). Patients with baseline Hb up to 11.0 g/dl and serum ferritin up to 500 ng/ml benefited from FCM treatment (stable Hb ≥11.0 g/dl). Also patients with ferritin >500 ng/ml but low transferrin saturation benefited from FCM treatment. FCM was well tolerated, 2.3% of patients reported putative drug-related adverse events. The substantial Hb increase and stabilisation at 11–12 g/dl in FCM-treated patients suggest a role for i.v. iron alone in anaemia correction in cancer patients.Keywords
This publication has 34 references indexed in Scilit:
- FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel DiseaseGastroenterology, 2011
- Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving ChemotherapyThe Oncologist, 2007
- EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 updateEuropean Journal Of Cancer, 2007
- The prevalence of iron deficiency among patients presenting with colorectal cancerColorectal Disease, 2005
- The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patientsEuropean Journal Of Cancer, 2004
- Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized TrialJournal of Clinical Oncology, 2004
- Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained womenThe American Journal of Clinical Nutrition, 2004
- Iron supplementation for unexplained fatigue in non-anaemic women: double blind randomised placebo controlled trialBMJ, 2003
- Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients.2002
- Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynxInternational Journal of Radiation Oncology*Biology*Physics, 2001